Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- Collagen (1)
- Diffuse (1)
- Disease Progression (1)
- EndoMT (1)
- Endothelial Mesenchymal Transition (1)
-
- Endothelial cell (1)
- Extracellular matrix (1)
- Fibrillar Collagens (1)
- Fibrotic diseases (1)
- Gene Expression (1)
- Humans (1)
- Idiopathic pulmonary fibrosis (1)
- Immunosuppressive Agents (1)
- Lung (1)
- Middle Aged (1)
- Mycophenolic Acid (1)
- Myofibroblast (1)
- Prognosis (1)
- Prospective Studies (1)
- Respiratory Function Tests (1)
- Scleroderma (1)
- Scleroderma, Diffuse (1)
- Skin (1)
- Systemic sclerosis (1)
- Time Factors (1)
- Transforming growth factor-β (1)
- Treatment Outcome (1)
Articles 1 - 2 of 2
Full-Text Articles in Medicine and Health Sciences
Endothelial To Mesenchymal Transition (Endomt) In The Pathogenesis Of Human Fibrotic Diseases., Sonsoles Piera-Velazquez, Fabian A. Mendoza, Sergio A. Jimenez
Endothelial To Mesenchymal Transition (Endomt) In The Pathogenesis Of Human Fibrotic Diseases., Sonsoles Piera-Velazquez, Fabian A. Mendoza, Sergio A. Jimenez
Jefferson Institute of Molecular Medicine Papers and Presentations
Fibrotic diseases encompass a wide spectrum of clinical entities including systemic fibrotic diseases such as systemic sclerosis, sclerodermatous graft versus host disease, nephrogenic systemic fibrosis, and IgG₄-associated sclerosing disease, as well as numerous organ-specific disorders including radiation-induced fibrosis, and cardiac, pulmonary, liver, and kidney fibrosis. Although their causative mechanisms are quite diverse, these diseases share the common feature of an uncontrolled and progressive accumulation of fibrous tissue macromolecules in affected organs leading to their dysfunction and ultimate failure. The pathogenesis of fibrotic diseases is complex and despite extensive investigation has remained elusive. Numerous studies have identified myofibroblasts as the cells …
A Prospective Observational Study Of Mycophenolate Mofetil Treatment In Progressive Diffuse Cutaneous Systemic Sclerosis Of Recent Onset., Fabian A. Mendoza, Md, Sarah J. Nagle, Jason B. Lee, Md, Sergio A. Jimenez
A Prospective Observational Study Of Mycophenolate Mofetil Treatment In Progressive Diffuse Cutaneous Systemic Sclerosis Of Recent Onset., Fabian A. Mendoza, Md, Sarah J. Nagle, Jason B. Lee, Md, Sergio A. Jimenez
Jefferson Institute of Molecular Medicine Papers and Presentations
OBJECTIVE: A prospective observational study of mycophenolate mofetil (MMF) treatment in patients with diffuse progressive cutaneous systemic sclerosis (SSc) of recent onset.
METHODS: Twenty-five previously untreated consecutive patients with recent-onset (< 24 mo) diffuse progressive cutaneous SSc received MMF as the only disease-modifying therapy. Modified Rodnan skin score (mRSS) and affected body surface area (BSA) were compared from initiation of MMF to study end. Pulmonary function tests performed at the same institution before therapy and at study end were available in 15 patients. Histopathology and real-time PCR assessment of fibrosis-related gene expression were performed before and after treatment in skin biopsies from 3 patients.
RESULTS: At 18.2 ± 8.73 months of MMF therapy (median 2000 mg/day) the mRSS decreased from 24.56 ± 8.62 to 14.52 ± 10.9 (p = 0.0004) and the affected BSA from 36% ± 16% to 14% ± 13.3% (p = 0.00001). Pulmonary function tests remained stable from initiation of MMF to the end of the study. Skin histopathology showed a remarkable reduction in accumulation of fibrotic tissue. Real-time PCR …